title: Carpal tunnel syndrome associated with interleukin-2 therapy.
abstract: BACKGROUND
  Interleukin (IL-2) has been extensively used in our institution in the treatment of cancer and has protean neurologic side effects. Carpal tunnel syndrome developing in patients receiving IL-2 appears to have a good prognosis and may spare the patient unneeded investigation.
  
  
  METHODS
  A retrospective evaluation was undertaken for all patients using our institution's Patient Studies database. The patients were examined and their charts reviewed.
  
  
  RESULTS
  We found eight patients with renal cell carcinoma who developed carpal tunnel syndrome (CTS) during treatment with IL-2, fluorouracil (5-FU), and alpha-interferon (alpha-IFN). The symptoms were bilateral in five patients and all patients improved with cessation of therapy. Three patients had recurrent symptoms with subsequent courses of therapy. Symptoms occurred during or shortly after IL-2 infusion and resolved after therapy was completed with conservative management. The number of courses given did not seem to correlate with development of symptoms. Neurophysiologic studies demonstrated conduction velocity slowing without evidence of acute denervation.
  
  
  CONCLUSIONS
  IL-2 can produce focal entrapment of the median nerve at the wrist, which reverses with drug withdrawal. IL-2 mediates the inflammatory response and can cause interstitial edema that likely causes CTS to develop in predisposed patients undergoing treatment.
authors.affiliation: Department of Neurology, University of Texas Medical School, Houston, USA.
authors.forename: V K
authors.initials: VK
authors.lastname: Puduvalli
authors.forename: A
authors.initials: A
authors.lastname: Sella
authors.forename: S G
authors.initials: SG
authors.lastname: Austin
authors.forename: A D
authors.initials: AD
authors.lastname: Forman
mesh_terms: D000328:Adult; D002292:Carcinoma, Renal Cell / Q000628:therapy; D002349:Carpal Tunnel Syndrome / Q000209:etiology*; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000628:therapy; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: D016898:Interferon-alpha; D007376:Interleukin-2; D005472:Fluorouracil